Literature DB >> 28925993

Targeted therapies: Survival ENDEAVORs.

Lisa Hutchinson.   

Abstract

Year:  2017        PMID： 28925993     DOI： 10.1038/nrclinonc.2017.155

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Authors:  Meletios A Dimopoulos; Hartmut Goldschmidt; Ruben Niesvizky; Douglas Joshua; Wee-Joo Chng; Albert Oriol; Robert Z Orlowski; Heinz Ludwig; Thierry Facon; Roman Hajek; Katja Weisel; Vania Hungria; Leonard Minuk; Shibao Feng; Anita Zahlten-Kumeli; Amy S Kimball; Philippe Moreau
Journal:  Lancet Oncol       Date:  2017-08-23       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.